Suggested remit - To evaluate the benefits and costs of ravulizumab within its marketing authorisation for treating paroxysmal nocturnal haemoglobinuria for national commissioning by NHS England
Status Proposed
Process HST
ID number 1457

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
02 November 2018 (10:00) Scoping workshop (London)
19 September 2018 - 17 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance